Rachael Lloyd

Oncology analyst @Datamonitor_HC. Views expressed are my own.

[Lucie Ellis-Taitt @LucieLEllis]

Death Excess Gives Pause To Merck & Co #Keytruda MM Phase III Studies £https://t.co/9mwwLJd3m1 @Merck #pharmanews #cancer

[Dominique Fontanilla @Datamonitor_DF]

Follow me, @BMTRobert, and @CitelineMariaB for #ASCO2017 updates starting tomorrow!

[FDA Drugs and Biologics @FDADrugs]

FDA approves new combination treatment for adults with acute myeloid leukemia (AML): https://t.co/CNTFvu1SNk.

[Robert Jeng @robert_jeng]

Opdivo (nivolumab) fails in CheckMate-143 for GBM. $BMY
https://t.co/5nrFyedDha

[Jack Allen @JohnK_Allen]

Proud to share our 1st DMHC podcast-Insights into $JUNO -0:17 $KITE -4:40 $RHHBY / $PBYI - 10:30 and $RHHBY - 15:44 https://t.co/76UBE0ISB2

[Amy Brenner @Epi_AmyB]

#Glioblastoma is rare and aggressive brain cancer with poor prognosis and urgent need for more effective therapies #RareDiseaseDay

[NICE @NICEComms]

We have reversed an earlier decision and now recommend ibrutinib, a CDF leukaemia drug, after price drop: https://t.co/kmoH6ebKTD

[Rachael Lloyd @Datamonitor_RL]

New #AML marketed and pipeline drug analysis available on the @Datamonitor_HC service (requires login) https://t.co/qBrEOnmpIA

[Rachael Lloyd @Datamonitor_RL]

Sunitinib's S-TRAC is the first positive trial in the adjuvant setting for RCC #ESMO16

[ESMO - Eur. Oncology @myESMO]

"A phase III trial is warranted to confirm the CABOSUN results" B. Escudier #ESMO16

[Rachael Lloyd @Datamonitor_RL]

Carbozantinib increases PFS by 2.6 months vs SOC sunitinib in first line advanced RCC in PII CABOSUN trial #ESMO16

[Robert Jeng @robert_jeng]

Custirsen fails P3 AFFINITY including originally promising poor prognosis pts. #ESMO16

[Rachael Lloyd @Datamonitor_RL]

@Datamonitor_JA The high cost of Opdivo/Yervoy combination may also be an issue, as well as toxicity associated with anti CTLA-4 therapy.

[Rachael Lloyd @Datamonitor_RL]

@Datamonitor_JA Opdivo/Yervoy will have demonstrate significant efficacy in untreated NSCLC to overcome Keytruda's lead in 1L setting.

[Jack Allen @JohnK_Allen]

$BMY pivots to combination approach for Opdivo in NSCLC after Checkmate-026,no significant improvement in patients w/50%PD-L1expression $MRK

[ESMO - Eur. Oncology @myESMO]

KEYNOTE 021 shows that PFS exceeds 1 year with pembrolizumab, carboplatin and pemetrexed as 1st line therapy in advanced #NSCLC #ESMO16

[ESMO - Eur. Oncology @myESMO]

KEYNOTE 024 shows superior efficacy of pembrolizumab over platinum-based chemo in first line for adv #NSCLC w high PD-L1 expression #ESMO16

[Rachael Lloyd @Datamonitor_RL]

Double hit for Opdivo in NSCLC as impressive data for Keytruda and Tecentriq are presented at #ESMO16

[Rachael Lloyd @Datamonitor_RL]

Queue to enter the presidential symposium session including results from the KEYNOTE024 trial of keytruda in NSCLC #ESMO16

[Rachael Lloyd @Datamonitor_RL]

Patient selection and optimal sequence of therapies will be key to the use of targeted endocrine combinations in ER+ MBC #ESMO16